Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic use of botulinum toxins types A and B

a technology of botulinum toxin and therapeutic use, which is applied in the field of methods for treating diseases of the nervous system, can solve the problems of local paralysis, muscle relaxation, and patients experiencing a loss of clinical responsiveness to botulinum toxin injections

Inactive Publication Date: 2005-06-16
AOKI K ROGER +3
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a method for treating various neuromuscular disorders or conditions such as strabismus, ocular motility disorders, dystonia, and spasms, by administering a therapeutically effective amount of a different serotype of botulinum toxin to a patient who has previously been treated with another serotype of botulinum toxin. This method can also be used when a patient has developed neutralizing antibodies to the initial treatment. The invention also provides compositions of the different serotype of botulinum toxins for injection into the patient."

Problems solved by technology

This results in local paralysis and hence relaxation of the muscle afflicted by spasm.
It has been found, however, that some patients experience a loss of clinical responsiveness to botulinum toxin injections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

The Use of Botulinum Toxin Serotype A, B and F in the Treatment of Tardive Dyskinesia

[0040] A patient, suffering from tardive dyskinesia resulting from the treatment with an antipsychotic drug, such as haloperidol, is treated with an effective amount of botulinum toxin type A by direct injection of such toxin into the muscles identified by the physician. After two to four days, the symptoms of tardive dyskinesia, i.e., orofacial dyskinesia, athetosis, dystonia, chorea, tics and facial grimacing, etc., are markedly reduced. Upon continued administration of the botulinum toxin type A, a loss of clinical response is noted. Thereafter, an effective amount of botulinum toxin type B is injected and the symptoms of tardive dyskinesia continue to be markedly reduced.

EXAMPLE 1(a)

[0041] The method of Example 1 is repeated, except that a patient suffering from tardive dyskinesia is injected with an effective amount of botulinum toxin type A, followed by injection of an effective amount of b...

example 1 (

EXAMPLE 1(d)

[0044] The method of Example 1 is repeated, except that a patient suffering from tardive dyskinesia is injected with an effective amount of botulinum toxin type A, followed by injection of an effective amount of botulinum toxin type F. Similar results are obtained.

example 2

Use of Botulinum Toxin in the Treatment of Spasmodic Torticollis

[0045] A male, suffering from spasmodic torticollis, as manifested by spasmodic or tonic contractions of the neck musculature, producing stereotyped abnormal deviations of the head, the chin being rotated to one side, and the shoulder being elevated toward the side at which the head is rotated, is treated by injection with up to about 300 units, or more, of botulinum toxin type E, (having an activity of one to four days) in the dystonic neck muscles. After the symptoms are substantially alleviated and the patient is able to hold his head and shoulder in a normal position, the patient develops antibodies. Thereafter the patient is injected with botulinum toxin type B and the symptoms continue to be substantially alleviated.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
frequencyaaaaaaaaaa
cell surface affinityaaaaaaaaaa
Login to View More

Abstract

A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.

Description

FIELD OF THE INVENTION [0001] The present invention provides novel methods for treating diseases of the nervous system, e.g., neuromuscular disorders and conditions, with botulinum toxins. In addition, the present invention provides methods useful in all tissue and organ systems which involve the release of neurotransmitters, especially acetylcholine. These cholinergic transmission systems include neuromuscular junctions (muscles), smooth muscles (gut, sphincters, etc.) and secretions (salivation and mucus). BACKGROUND OF THE INVENTION [0002] A bacterial toxin, botulinum toxin, in particular botulinum toxin type A, has been used in the treatment of a number of neuromuscular disorders and conditions involving muscular spasm; for example, strabismus, blepharospasm, spasmodic torticollis (cervical dystonia), oromandibular dystonia and spasmodic dysphonia (laryngeal dystonia). The toxin binds rapidly and strongly to presynaptic cholinergic nerve terminals and inhibits the exocytosis of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61K35/74A61K38/16A61K38/48A61P21/00A61P21/02A61P25/00
CPCA61K38/4893A61P21/00A61P21/02A61P25/00A61P25/02A61P25/16A61P27/02A61P29/00A61P43/00Y02A50/30
Inventor AOKI, K. ROGERGRAYSTON, MICHAEL W.CARLSON, STEVEN R.LEON, JUDITH M.
Owner AOKI K ROGER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com